Cetuximab I-131

Drug Profile

Cetuximab I-131

Alternative Names: 131I-Cetuximab; Cetuximab-I131; Iodine-131-cetuximab

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator Pacific Meinuoke Biopharmaceutical
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Epidermal growth factor inhibitors; Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Colorectal cancer

Most Recent Events

  • 18 Jan 2016 Investigation in Colorectal cancer in China (unspecified route) prior to January 2016 (Pacific Meinuoke pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top